953410-86-1

Basic information

• Product Name: 1H-Indazole, 5-bromo-7-iodo-
• Synonyms: 1H-Indazole, 5-bromo-7-iodo-;5-Bromo-7-iodo-1H-indazole
• CAS NO: 953410-86-1
• Molecular Formula: C₇H₄BrIN₂
• Molecular Weight: 322.92853
• Mol File: 953410-86-1.mol

Chemical Properties

• Boiling Point: 410.4±30.0 °C(Predicted)
• Appearance: /
• Density: 2.421±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 10.78±0.40(Predicted)
• CAS DataBase Reference: 1H-Indazole, 5-bromo-7-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole, 5-bromo-7-iodo-(953410-86-1)
• EPA Substance Registry System: 1H-Indazole, 5-bromo-7-iodo-(953410-86-1)

Safety Data

• Hazardous Substances Data: 953410-86-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Indazole, 5-bromo-7-iodois used as a building block in organic synthesis for the creation of various complex organic molecules. Its unique structure and functional groups make it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Drug Development:
1H-Indazole, 5-bromo-7-iodois used as a starting material in the development of pharmaceutical drugs. Its potential pharmacological activities have been studied, and it has been investigated for its use in the treatment of various diseases and conditions.
Used in Chemical Reactions as a Substrate:
1H-Indazole, 5-bromo-7-iodois used as a substrate in various chemical reactions in the laboratory. Its reactivity and functional groups make it suitable for use in a wide range of reactions, including cross-coupling, substitution, and addition reactions.
Used in Catalyst Development:
1H-Indazole, 5-bromo-7-iodohas been investigated for its potential as a catalyst in organic reactions. Its unique properties and reactivity make it a promising candidate for the development of new and efficient catalytic systems in organic synthesis.

Upstream product

• 583-75-5 4-Bromo-2-methylaniline 
• 922170-67-0 4-bromo-2-iodo-6-methylaniline 

Relevant articles and documents

Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay

Inappropriate activation of endosomal TLR7 and TLR8 occurs in several autoimmune diseases, in particular systemic lupus erythematosus (SLE). Herein, the development of a TLR8 antagonist competition assay and its application for hit generation of dual TLR7

ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES

The present invention relates to pyrazole fused-ring derivatives, their preparation methods, and use thereof in medicine. In particular, the present invention relates to a novel derivative represented by formula (I), and a pharmaceutically acceptable salt

2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization

We describe structure-based optimization of a series of novel 2,4-diaminopyrimidine MK2 inhibitors. Co-crystal structures (see accompanying Letter) demonstrated a unique inhibitor binding mode. Resulting inhibitors had IC50 values as low as 19 nM and moderate selectivity against a kinase panel. Compounds 15, 31a, and 31b inhibit TNFα production in peripheral human monocytes.